Christine Fischette, Ph.D.

Christine Fischette, Ph.D. has a long and distinguished career in the pharmaceutical and biotechnology industries. Christine began their career in 1983 as a Senior Scientist at Hoffman-La Roche. Christine then moved on to Pfizer in 1987, where they held the roles of Global Business Development & Licensing Team Leader/Director. In 1999, they became the Head of Negotiation, Global Business Development & Licensing at Novartis. In 2008, they were appointed President of Enzo Therapeutics, Inc. and in 2010 became the CEO of BioLinkUp, LLC, as well as Senior Advisor at Griffin Securities, Inc. In 2015, they took on the role of Executive Director at Torreya Partners, and in 2021 they were appointed Director at Antag Therapeutics. Most recently, in 2022, they joined the Advisory Board at Concord Engineering Group, Inc.

Christine Fischette, Ph.D. obtained their Ph.D. in Physiology from the University of Medicine and Dentistry of New Jersey/Rutgers Biomedical Health Sciences in 1979. Prior to that, they obtained a Bachelor's degree in Biology Education from Rutgers University - Newark.